Bringing together researchers from Italy and the US, Chroma Medicine has emerged out of stealth with series A financing led by Cormorant Asset Management.

Chroma Medicine, a US-based epigenetic editing technology developer exploiting research from multiple institutions, has launched with $125m in series A financing led by hedge fund Cormorant Asset Management.

Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T Rowe Price Associates, Wellington Management, Atlas Venture, Newpath Partners and Sofinnova Partners all backed the round.

The latter three had previously provided seed capital, Chroma disclosed in its launch announcement without offering further details.

Founded in May 2020, Chroma…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in